Maher Masoud - Jan 3, 2024 Form 4 Insider Report for MAXCYTE, INC. (MXCT)

Role: President and CEO, Director
Signature: /s/ Katie Kazem, Attorney-in-Fact
Stock symbol: MXCT
Transactions as of: Jan 3, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/4/2024, 04:30 PM
Previous filing: Mar 21, 2023
Next filing: Jun 10, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MXCT	Employee Stock Option (right to buy)	Award	$0	+400K		$0.00	400K	Jan 3, 2024	Common Stock	400K	$4.42	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option grant was made pursuant to the terms of the letter agreement, dated as of December 11, 2023, by and between the Issuer and the reporting person, entered into in connection with his appointment as President and Chief Executive Officer of the Issuer, as set forth in a Current Report on Form 8-K filed by the Issuer on December 11, 2023. Of the shares underlying the option, 25% will vest on January 2, 2025 and the remaining 75% will vest in 36 equal monthly installments thereafter, in each case subject to the reporting person's continuous service with the Issuer at the applicable vesting date.

Content

This option grant was made pursuant to the terms of the letter agreement, dated as of December 11, 2023, by and between the Issuer and the reporting person, entered into in connection with his appointment as President and Chief Executive Officer of the Issuer, as set forth in a Current Report on Form 8-K filed by the Issuer on December 11, 2023. Of the shares underlying the option, 25% will vest on January 2, 2025 and the remaining 75% will vest in 36 equal monthly installments thereafter, in each case subject to the reporting person's continuous service with the Issuer at the applicable vesting date.